Company Description
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 408 |
| CEO | Marianne De Backer |
Contact Details
Address: 1800 Owens Street, Suite 900 San Francisco, California 94158 United States | |
| Phone | 415 906 4324 |
| Website | vir.bio |
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| Employer ID | 81-2730369 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer and Director |
| Jason O'Byrne M.B.A. | Executive Vice President and Chief Financial Officer |
| Vanina de Verneuil J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Mark D. Eisner M.D., M.P.H. | Executive Vice President and Chief Medical Officer |
| Dr. Lawrence Corey M.D. | Co-Founder and Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder and Scientific Advisor |
| Brent Sabatini | Senior Vice President, Principal Accounting Officer and Chief Accounting Officer |
| Dr. Maninder Hora Ph.D. | Executive Vice President and Chief Technical Operations Officer |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President and Chief Scientific Officer |
| Toby Medaris | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 144 | Filing |
| Jul 15, 2025 | 144 | Filing |
| Jul 1, 2025 | 144 | Filing |
| Jun 11, 2025 | 144 | Filing |
| Jun 10, 2025 | 144 | Filing |
| Jun 9, 2025 | 144 | Filing |
| Jun 2, 2025 | 144 | Filing |
| May 29, 2025 | 8-K | Current Report |
| May 9, 2025 | 8-K | Current Report |